In this issue:
Effects of dapagliflozin on hospitalisations in type 2 diabetics
ONWARDS 1–4 RCTs of icodec vs. glargine/degludec for type 2 diabetes
Major adverse CV event risks among antihyperglycaemic classes
Residual insulin secretion in type 1 diabetes
NASH and advanced fibrosis in type 2 diabetes
Tirzepatide vs. glargine as second-or third-line for type 2 diabetes in Asia-Pacific
Oral orforglipron for type 2 diabetes
Please login below to download this issue (PDF)